MiRNAs dysregulated in triple-negative breast cancer
The invention provides methods of diagnosing and treating cancer in a subject. The inventors have identified a series of dysregulated miRNAs that are indicative of triple-negative breast cancer. In some embodiments, the invention further provides for the administration of a cancer therapy to the subject.
1. A method of identifying “triple-negative” breast cancer in a subject comprising:
(a) obtaining a breast cancer tissue sample from said subject; and
(b) assessing said sample for one or more miRNAs selected from the group consisting of miR-193b, miR-34a, miR-301a, miR-148a and/or miR-15b;
wherein decreased levels of one or more of miR-193b, miR-34a, miR-301a, miR-148a and/or miR-15b in said sample, as compared to a luminal breast cancer, indicates that said subject has a “triple-negative” breast cancer.
2. The method of claim 1 , wherein said sample is a biopsy or resected tumor tissue.
3. The method of claim 1 , wherein one, two, three or four of said miRNAs are assessed.
4. The method of claim 1 , wherein each of miR-193b, miR-34a, miR-301a, miR-148a and miR-15b are assessed.
5. The method of claim 1 , wherein one, two, three or four of said miRNAs are decreased.
6. The method of claim 1 , wherein each of miR-193b, miR-34a, miR-301a, miR-148a and miR-15b are decreased.
7. The method of claim 1 , wherein said subject is determined not to have “triple-negative” breast cancer, and further comprising administering to said subject a treatment for ER-positive breast cancer.
8. The method of claim 1 , wherein said subject is determined to have “triple-negative” breast cancer, and further comprising administering to said subject a treatment for “triple-negative” breast cancer.
9. The method of claim 8 , wherein if said subject exhibits reduced miR-193b, said subject is treated with a fatty acid synthase inhibitor.
10. The method of claim 9 , wherein said inhibitor is miR-193b, c75 or Orlistat®.
11. The method of claim 8 , wherein if said subject exhibits reduced miR-34a, said subject is treated with miR-34a.
12. The method of claim 8 , wherein if said subject exhibits reduced miR-301a, said subject is treated with miR-301a.
13. The method of claim 8 , wherein if said subject exhibits reduced miR-148a, said subject is treated with miR-148a.
14. The method of claim 8 , wherein if said subject exhibits reduced miR-15b, said subject is treated with miR-15b.